What is Castle Biosciences's revenue?

Castle Biosciences (CSTL) generated $339.9M in revenue over the trailing twelve months, down 2.1% year over year.

Is Castle Biosciences profitable?

Castle Biosciences is not currently profitable: it reported a net loss of $12.8M over the trailing twelve months, a -3.8% net margin.

What are Castle Biosciences's profit margins?

Gross margin is 77.9% and operating margin is -9.8%, with a -3.8% net margin.

What is Castle Biosciences's earnings per share?

Castle Biosciences's diluted EPS over the trailing twelve months is $-0.43.

Where does Castle Biosciences's income statement data come from?

Every line is extracted from Castle Biosciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Castle Biosciences CSTL Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Total revenue	$344.23M+3.7%	$332.07M+51.1%	$219.79M+60.4%	$137.04M+45.7%
Total cost of revenue	$71.03M+18.0%	$60.21M+33.8%	$44.98M+40.5%	$32.01M+102%
Research and development	$51.85M-0.4%	$52.04M-2.9%	$53.62M+19.4%	$44.9M+51.5%
Selling, general and administrative	$229.32M+14.6%	$200.05M+11.0%	$180.15M+26.0%	$143M+64.9%
Depreciation and amortization	$34.84M+214%	$11.11M+23.2%	$9.01M+9.0%	$8.27M+322%
Operating income	-$42.81M-594%	$8.67M+113%	-$67.98M+6.7%	-$72.86M-81.8%
Operating margin	-12.4%-15.0pp	2.6%+33.5pp	-30.9%+22.2pp	-53.2%-10.6pp
Interest expense	$86K-85.1%	$577K+5,145%	$11K-35.3%	$17K+1,600%
Interest income	$11.77M-8.9%	$12.92M+21.6%	$10.62M+168%	$3.97M+5,735%
Other income (expense), net	$144K—	——	$0—	——
Net investment gains (losses)	——	$555K—	$0—	——
Income tax expense	-$5.36M—	——	$101K+106%	-$1.82M+79.1%
Net income	-$24.16M-232%	$18.25M+132%	-$57.47M+14.4%	-$67.14M-115%
Net margin	-7%-12.5pp	5.5%+31.6pp	-26.1%+22.8pp	-49%-15.7pp
Diluted earnings per share	-$0.84-235%	$0.62+129%	-$2.15+17.0%	-$2.59-109%
Basic earnings per share	-$0.83-226%	$0.66+131%	-$2.15+17.0%	-$2.59-109%
Weighted-average shares, diluted	116.2M+1.2%	114.9M+7.4%	107M+3.0%	103.9M+3.4%
Weighted-average shares, basic	115.6M+4.4%	110.7M+3.5%	107M+3.0%	103.9M+3.4%
Operating Expenses, Net Of Other Operating Income	$387.04M+19.7%	$323.4M+12.4%	$287.77M+37.1%	$209.89M+56.4%
Other income, net (Note 6)	$144K—	——	$0—	——
Revenue From Contract With Customer Excluding Assessed Tax	$344.23M+3.7%	$332.07M+51.1%	$219.79M+60.4%	$137.04M+45.7%
EBIT	-$42.81M-594%	$8.67M+113%	-$67.98M+6.7%	-$72.86M-81.8%
EBITDA	-$2.04M-108%	$24.67M+144%	-$55.65M+10.7%	-$62.31M-69.9%
EBITDA	-$2.04M-108%	$24.67M+144%	-$55.65M+10.7%	-$62.31M-69.9%
EBITDA margin	-0.6%-8.0pp	7.4%+32.7pp	-25.3%+20.2pp	-45.5%-6.5pp
EBIT	-$42.81M-594%	$8.67M+113%	-$67.98M+6.7%	-$72.86M-81.8%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Castle Biosciences.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Castle Biosciences's revenue?: Castle Biosciences (CSTL) generated $339.9M in revenue over the trailing twelve months, down 2.1% year over year.
Is Castle Biosciences profitable?: Castle Biosciences is not currently profitable: it reported a net loss of $12.8M over the trailing twelve months, a -3.8% net margin.
What are Castle Biosciences's profit margins?: Gross margin is 77.9% and operating margin is -9.8%, with a -3.8% net margin.
What is Castle Biosciences's earnings per share?: Castle Biosciences's diluted EPS over the trailing twelve months is $-0.43.
Where does Castle Biosciences's income statement data come from?: Every line is extracted from Castle Biosciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.